High Dose [F-18]-fluorodeoxyglucose (FDG) PET/CT Based Imaged-Guided Intensity-Modulated Radiotherapy (IG-IMRT) with Concurrent Paclitaxel (P) and Carboplatin (C) in Locally Advanced Non-Small-Cell Lung Cancer (LANSCLC): A Dose-Finding Phase I Study
T. Zhang,G. Zhao,Y. Xu,Y. Liu,Z. Chen,N. Cheng,G. Yan,Y. Hu,Y. Chen,S. Yao,Z. Hu,X. Chen,T. Chen
DOI: https://doi.org/10.1016/j.ijrobp.2019.06.147
2019-01-01
Abstract:Given that a biological equivalent dose (BED) ≥ 100 Gy achieves local control of more than 90% in early-stage NSCLC, resulting in significantly improved overall survival. This BED or even higher is logically required to control local disease for LANSCLC, whose tumors are often larger. However, dose escalation is limited by the risk of normal tissue toxicity as demonstrated in RTOG O617. FDG PET-CT can identify residual metabolic disease (RMD). Hyperfractionated RT allows for delivering a higher dose without increasing late toxicity. IMRT may better protect normal tissue. We hypothesized that use of a hyperfractionated RT boost (HFRT) to only RMD following standard chemoradiotherapy (SCRT) using PET/CT based IG-IMRT could potentially increase the total radiation dose. The primary objective of this trial was to define maximum tolerated dose (MTD) of HFRT boost concurrent with weekly P/C. Eligible patients (pts) with LANSCLC were treated with upfront SCRT consisting of weekly P at 45 mg/m2 and C AUC 2 with concurrent 60 Gy of preirradiation PET/CT based IG-IMRT for 6 weeks. A repeat FDG PET/CT scan was performed between fractions 29 and 30. Pts achieving complete metabolic response (CMR) discontinued RT. Individuals with RMD (defined as any residual FDG uptake within the tumor higher than uptake in the normal mediastinal blood pool or in the irradiated lung tissue abutting the tumor on the repeat PET/CT) received a HFRT boost on day 43 to RMD concurrent with the same chemotherapy regimen. The boost doses were escalated in increments of 4.8 Gy delivered in 4 twice daily fractions of 1.2 Gy using a modified Fibonacci design. A minimum of 6-weeks follow-up were required after completion of RT before proceeding to the next dose. Every effort was taken to limit dose to the heart and lung. Dose limiting toxicity (DLT) was defined as protocol treatment-related grade (G) ≥ 4 esophagitis or any other G ≥ 3 non-hematological toxicity or G ≥ 4 hematological toxicity lasting more than 7 days. MTD was defined as the highest dose at which ≤ 1 pts experienced DLT. All pts received adjuvant chemotherapy for two cycles 6 weeks after completion of HFRT. Thirty-three pts were assessable. SCRT was well tolerated and 5 pts achieved CMR. The incidence of DLT was 0/3, 1/6 (G3 pneumotitis), 0/3, 0/3, 0/3, 1/10 (G4 pneumotitis) at 4.8, 9.6, 14.4, 19.2, 24, 28.8 Gy, respectively. The MTD wasn't reached. The most common acute G ≥ 3 toxicities were neutropenia (24%) and esophagitis (18%). Late toxicity was mild. No pts experienced symptomatic cardiotoxicity. The overall response rate was 82% (95% CI, 68%-96%). With a median follow up of 10 months (range, 6-21),locoregional failure only (LRF), LRF and distant failure (DF), and DF only were noted in 1, 2, and 6 pts, respectively. There was a 28.8 Gy of HFRT boost to the RMD after 60 Gy of SCRT using PET/CT based IG-IMRT , resulting in the total composite tumor dose of 88.8 Gy (calculated BED 104 Gy without time correction, using α/β = 10 for tumor), can be safely delivered with concurrent P/C.